Prosecution Insights
Last updated: April 19, 2026

Apogee Biotechnology Corporation

1 pending office actions

Portfolio Summary

1
Total Pending OAs
1
Final Rejections
0
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17422647 COMBINATION OF A SK2 INHIBITOR AND AN INHIBITOR OF A CHECKPOINT PATHWAY, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF SEITZ, ANTHONY JOSEPH 1629 Final Rejection Jul 13, 2021

Managing Apogee Biotechnology Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month